ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Triple-Negative Breast Cancer Cells Resist Natural Killer Cell-Mediated Killing Through Interleukin-11 Trans-Signaling.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of Novel piR-2158 Isoforms and Their Distinct Antitumor Effects on Triple-Negative Breast Cancer.Cancers · 2026Article
- Triple-Negative Breast Cancer Cells Resist Natural Killer Cell-Mediated Killing Through Interleukin-11 Trans-Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Natural killer (NK) cell-based therapies show great promise for treating triple-negative breast cancer (TNBC). However, in the tumor microenvironment, some TNBC cells develop resistance to NK cell-mediated killing and contribute to NK cell exhaustion. In this study, TNBC cell populations are isolated that can resist NK cell attacks and uncovered the underlying mechanisms. It is found that these resistant TNBC cells secrete high levels of interleukin-11 (IL-11). IL-11 acts through a process known as trans-signaling by forming complexes with the soluble IL-11 receptor (sIL-11R) and engaging the gp130 receptor on NK cells. This trans-signaling activates the JAK1/STAT1/3 pathway, leading to the upregulation of p21 and subsequent cell cycle arrest in NK cells. As a result, the proliferation and IFNγ production of NK cells are inhibited, enabling TNBC cells to resist NK cell-mediated killing. Disrupting IL-11 or sIL-11R in TNBC cells restores NK cell activity. Importantly, it is also found that IL-11 expression is elevated in human TNBC tissues and negatively correlated with the number of NK cells in the tumor microenvironment. These findings identify IL-11 trans-signaling as a novel mechanism of immune evasion in TNBC and suggest that targeting this pathway may enhance the effectiveness of NK cell-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.